Abstract:Summary Background Leritrelvir is a novel α-ketoamide based peptidomimetic inhibitor of SARS-CoV-2 main protease. A preclinical study has demonstrated leritrelvir poses similar antiviral activities towards different SARS-CoV-2 variants compared with nirmatrelvir. A phase 2 clinical trial has shown a comparable antiviral efficacy and safety between leritrelvir with and without ritonavir co-administration. This trial aims to test efficacy and safety of leritrelvir monotherapy in adults with mild-to-moderate COVID-19. Methods This was a randomised, double-blind, placebo-controlled, multicentre phase 3 trial at 29 clinical sites in China. Enrolled patients were from 18 to 75 years old, diagnosed with mild or moderate COVID-19 and not requiring hospitalization. Patients had a positive SARS-CoV-2 nucleic acid test (NAT) and at least one of the COVID-19 symptoms within 48 h before randomization, and the interval between the first positive SARS-CoV-2 NAT and randomization was ≤120 h (5 days). Patients were randomly assigned in a 1:1 ratio to receive a 5-day course of either oral leritrelvir 400 mg TID or placebo. The primary efficacy endpoint was the time from the first dose to sustained clinical recovery of all 11 symptoms (stuffy or runny nose, sore throat, shortness of breath or dyspnea, cough, muscle or body aches, headache, chills, fever ≥37 °C, nausea, vomiting, and diarrhea). The safety endpoint was the incidence of adverse events (AE). Primary and safety analyses were performed in the intention-to-treat (ITT) population. This study is registered with ClinicalTrials.gov , NCT05620160 . Findings Between Nov 12 and Dec 30, 2022 when the zero COVID policy was abolished nationwide, a total of 1359 patients underwent randomization, 680 were assigned to leritrelvir group and 679 to placebo group. The median time to sustained clinical recovery in leritrelvir group was significantly shorter (251.02 h [IQR 188.95–428.68 h]) than that of Placebo (271.33 h [IQR 219.00–529.63 h], P = 0.0022, hazard ratio [HR] 1.20, 95% confidence interval [CI], 1.07–1.35). Further analysis of subgroups for the median time to sustained clinical recovery revealed that (1) subgroup with positive viral nucleic acid tested ≤72 h had a 33.9 h difference in leritrelvir group than that of placebo; (2) the subgroup with baseline viral load >8 log 10 Copies/mL in leritrelvir group had 51.3 h difference than that of placebo. Leritrelvir reduced viral load by 0.82 log10 on day 4 compared to placebo. No participants in either group progressed to severe COVID-19 by day 29. Adverse events were reported in two groups: leritrelvir 315 (46.46%) compared with placebo 292 (43.52%). Treatment-relevant AEs were similar 218 (32.15%) in the leritrelvir group and 186 (27.72%) in placebo. Two cases of COVID-19 pneumonia were reported in placebo group, and one case in leritrelvir group, none of them were considered by the investigators to be leritrelvir related. The most frequently reported AEs (occurring in ≥5% of participants in at least one group) were laboratory finding: hypertriglyceridemia (leritrelvir 79 [11.7%] vs . placebo 70 [10.4%]) and hyperlipidemia (60 [8.8%] vs . 52 [7.7%]); all of them were nonserious. Interpretation Leritrelvir monotherapy has good efficacy for mild-to-moderate COVID-19 and without serious safety concerns. Funding This study was funded by the National Multidisciplinary Innovation Team Project of Traditional Chinese Medicine , Guangdong Science and Technology Foundation , Guangzhou Science and Technology Planning Project and R&D Program of Guangzhou Laboratory .

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19

Olgotrelvir As a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.

A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects

Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China

Simnotrelvir as a potential treatment for COVID-19

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial

Clinical effectiveness and safety of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in the treatment of moderate to severe COVID-19 patients

Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir

Effect of use of oral antiviral agents on reducing critical illness and mortality for patients with moderate to severe COVID-19

Efficacy and Safety of SIM0417 (SSD8432) Plus Ritonavir for COVID-19 Treatment: a Randomised, Double-Blind, Placebo-Controlled, Phase 1b Trial

Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Early antiviral therapy of abidor combined with lopinavir/ritonavir and re combinant interferonα 2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study

Efficacy and Safety of 5-Day Oral Ensitrelvir for Mild to Moderate COVID-19

Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18–60 years

Early antiviral therapy of abidol combined with lopinavir/ritonavir and recombinant interferon α-2b for patients with COVID-19 in Zhejiang: A multicenter prospective study

Comparison of the effectiveness of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the treatment of COVID-19 moderate hospitalized patients with severe high-risk factors

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Small-molecule antivirals treatment for COVID-19: A systematic review and network meta-analysis